Feb 04,2016

Ahead of IPO, Senseonics taps diasend for CGM app integration

Senseonics recently announced a partnership with diasend, a Swedish diabetes data management company. Diasend integrates data from a number of different glucometers, CGMs, and insulin pumps and pulls that data into a consumer app for Apple and Android.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 25,2016

Insulet Announces Development Partner for the OmniPod Artificial Pancreas

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced a license agreement and partnership with Mode AGC (Automated Glucose Control LLC), to develop and incorporate the advanced artificial pancreas algorithm created by renowned researchers Francis Doyle PhD, Eyal Dassau PhD, and Howard Zisser MD. Insulet's artificial pancreas system will use the innovative and differentiated OmniPod platform, the latest DexCom Continuous Glucose Monitoring (CGM) technology and the algorithm licensed from Mode AGC.

COLLABORATION PARTNERSHIP

#r&d

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 31,2016

Stanford study: Dexcom CGM, HealthKit, and Epic can improve glycemic control in kids, teens

A group of Stanford physicians and researchers has published a study in the Journal of the American Medical Informatics Association detailing their experience setting up continuous glucose monitoring with a Dexcom G4 CGM, Apple HealthKit, and Epic.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 14,2016

Dexcom G5® Mobile Continuous Glucose Monitoring System Now Available on the Apple Watch

Dexcom, Inc., (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for people with diabetes, announced today that the Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System will support the Apple Watch enabling users to monitor their G5 Mobile glucose data using the app with one glance of their wrist. Users, as well as parents and caregivers, will be able to discreetly receive glucose readings and trends, alerts and notifications on Apple Watch, which syncs data directly from iPhone.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 15,2016

Nemaura Medical Announces receipt of notification of CE Approval for its sugarBEAT® Continuous Glucose Monitoring System

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally invasive wireless continuous glucose monitoring (“CGM”) system known as sugarBEAT®, announced today that it has received notification of CE Approval for its sugarBEAT® system from its European Notified Body.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 15,2016

Interim Clinical Data on Increased Measurement Frequency for sugarBEAT® CGM Released by Nemaura Medical

Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT®, today announced further interim clinical data based on increased measurement frequency. The sugarBEAT® skin-patch is designed to display real time glucose readings on a reader via blue tooth, or allow retrospective data evaluation on a reader or mobile phone App. Nemaura today issued results of an interim study of eight patient day visits, consisting of five Type I diabetics, two of whom made two visits each, and one Type II insulin dependent diabetic patient, with up to 12 hours device wear time per day.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 11,2016

Senseonics receives CE Mark for implantable continuous glucose monitoring system

Senseonics, a Germantown, Maryland-based company working on a longterm implantable continuous glucose monitor, has received a CE Mark for its Eversense Continuous Glucose Monitoring (CGM) System.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
May 25,2016

Medtronic taps Qualcomm to build smaller, cheaper continuous glucose monitors

Medtronic announced that it will work with Qualcomm Life to develop a new generation of smaller, affordable continuous glucose monitors (CGMs) for people with Type 2 diabetes, the companies announced today. Currently, CGM devices are mostly prescribed for people with Type 1 diabetes, while those with Type 2 are more likely to use discrete finger-prick glucometers. However, this new partnership aims to leverage Qualcomm's expertise to develop CGMs that are smaller, easier to use, and more affordable than currently available CGMs -- in the hopes of making the technology available to those with Type 2 diabetes, an addressable market more than 20 times larger.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 19,2016

Medtronic gets CE Mark for smartphone-connected CGM

Medtronic has received a CE Mark for its Guardian Connect mobile continuous glucose monitor (CGM) and app. The company will begin selling the system in select countries in Europe, Asia, and Latin America in Q2 2017 and expects to receive FDA clearance to launch the device in the US around that same time.

REGULATORY CE MARK

#cgm

#mobile app

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 04,2016

Nemaura Medical Inc., completes second FDA Pre-submission meeting and appoints Navigant to submit IDE for Nemaura’s sugarBEAT® system

Nemaura Medical Inc., a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT®, today announced that it recently held a second pre-submission meeting with the FDA to discuss the clinical program for its sugarBEAT® system, for the purpose of a PMA submission in the USA. Nemaura Medical anticipates completing the clinical program and submitting the PMA application around mid 2017.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM